Researchers demonstrated for the first time that a microRNA component of this region—miR-383—is frequently downregulated in prostate cancer, has a critical role in determining tumor-initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of prostate cancer tumor-initiating cells/stem cells. [Oncogene]
Abstract

Researchers examined the effect of nimbolide at 1 and 2 μM concentrations on TNF-α/TNFR1 mediated signaling molecules involved in cell survival and proliferation in PC-3 cell line via NF-κB and MAPK pathways by real time PCR and western blot. [Biomed Pharmacother]
Abstract

CLINICAL RESEARCH

The author provides data on serine/threonine protein kinase (STK) expression and activity in the development of castration resistant disease as well as summarizes recent reports of different strategies to block STK activity for the control of prostate cancer progression. [Expert Opin Investig Drugs]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the prostate cell research field.

MDNA Life Sciences Inc. announced that it has entered into a license agreement with Phi Life Sciences. Under the agreement, Phi is the first US partner to distribute MDNA’s proprietary liquid biopsy test for prostate cancer, the Prostate Mitomic Test. [MDNA Life Sciences Inc. (PR Newswire Association LLC)]
Press Release

The Department of Veterans Affairs (VA) announced an a $50-million precision oncology initiative and substantial partnership with the Prostate Cancer Foundation (PCF) to prevent, screen and promote research to speed the development of treatments and cures for prostate cancer among Veterans. [Prostate Cancer Foundation]
Press Release

The V Foundation for Cancer Research announced a new partnership with the San Francisco-based BRCA Foundation and the Gray Foundation to fund research of cancers that derive from BRCA or BRCA-like mutations. Each organization will provide a $1.5 million challenge to the V Foundation for BRCA Research Collaborative Grants. This research will advance the study of inherited mutations in BRCA1 and BRCA2, genes that produce tumor suppressor proteins. [The V Foundation for Cancer Research]
Press Release

Dr. John H. Lynch, prominent urologist and prostate cancer survivor, testified before Congress on behalf of the American Urological Association during a special hearing titled, “Examining the United States Preventive Services Task Force.” The hearing was called by the House Energy & Commerce Subcommittee on Health and specifically referenced the USPSTF Transparency and Accountability Act, introduced by Reps. Marsha Blackburn and Bobby Rush. [American Urological Association (PR Newswire Association LLC)]
Press Release

Legislation that would streamline research and development at the US National Institutes of Health and drug regulation at the Food and Drug Administration is one step closer to becoming law. The US House of Representatives approved the nearly 1,000-page bill — known as the 21st Century Cures Act — on 30 November. The Senate is expected to take up the controversial US$6.3-billion measure as early as next week. [Nature News]
Editorial

Institutions struggle to respond after court blocks regulations that would have increased wages for junior researchers. Some universities are proceeding with planned salary increases for postdocs, but others have cancelled — or at least, temporarily halted — changes to researchers’ pay. The uncertainty over how the legal battle will play out is already affecting some postdocs’ career and family plans. [Nature News]
Editorial

The country’s top drug regulators pushed back on claims they move too slowly in approving new stem cell treatments and sought to temper expectations for the field’s potential to benefit patients, emphasizing the hazards and the unknowns that persist with developing such therapies. [STAT News]
Editorial

The 4D Nucleome, a major research consortium funded by the US National Institutes of Health, is now requiring that all manuscripts related to its US$120-million, five-year program are posted to an online preprint server ahead of peer review. And a privately funded, US$600-million biomedical research initiative in California is considering whether to demand its investigators do the same. [Nature News]
Editorial